Document:

EXHIBIT 10.1

 

AMENDMENT
TO THE

EMPLOYMENT
AGREEMENT BY AND BETWEEN

JOÃO
SIFFERT, M.D. AND ABEONA THERAPEUTICS INC.

 

This
AMENDMENT, dated as of the 12th day of September, 2019, is made by and between ABEONA THERAPEUTICS INC. (“Abeona”)
and João Siffert, M.D. (“Siffert”).

 

WITNESSETH:

 

WHEREAS,
Abeona and Siffert entered into that certain Employment Agreement, dated as of February 11, 2019 (“Agreement”);

 

WHEREAS,
Abeona and Siffert desire to amend the Agreement.

 

NOW,
THEREFORE, Abeona and Siffert hereby agree to amend the Agreement as follows:

 

1.
The third sentence of the first paragraph of Section 4 of the Agreement is hereby amended to read in its entirety as follows:

 

“If
you remain continuously employed from the Effective Date through the date of a Change in Control (as defined below), notwithstanding
the terms of any equity incentive plan or award agreements, as applicable, all outstanding unvested stock options/stock appreciation
rights granted to your during your employment with the Company shall become fully vested and exercisable immediately prior to
the date of the Change in Control.”

 

2.
From and after the execution of this Amendment, all references in the Agreement to “this Agreement,” “hereof,”
“herein,” and similar words or phrases shall mean and refer to the Agreement as amended, including this Amendment.
This Amendment shall not be modified, supplemented, amended, or terminated in any manner whatsoever, except by a written instrument
signed by the party against which such modification, supplement, amendment, or termination is sought to be enforced.

 

3.
Except as expressly modified by this Amendment, all other terms and conditions of the Agreement shall remain in full force and
effect.

 

IN
WITNESS WHEREOF, Abeona and Siffert have caused this Amendment to be executed by their respective duly authorized officers as
of the date first above written.

 

	/s/
    João Siffert, M.D.	 	ABEONA
    THERAPEUTICS INC.
	João
    Siffert, M.D.	 	By:	/s/
    Steven H. Rouhandeh
	 	 	Name: 	Steven
    H. Rouhandeh
	 	 	Title:	Executive
    ChairmanEXHIBIT 10.2

 

AMENDMENT
TO THE

EMPLOYMENT
AGREEMENT BY AND BETWEEN

CHRISTINE
BERNI SILVERSTEIN AND ABEONA THERAPEUTICS INC.

 

This
AMENDMENT, dated as of the 12th day of September, 2019, is made by and between ABEONA THERAPEUTICS INC. (“Abeona”)
and Christine Berni Silverstein (“Silverstein”).

 

WITNESSETH:

 

WHEREAS,
Abeona and Silverstein entered into that certain Employment Agreement, dated as of January 8, 2019 (“Agreement”);

 

WHEREAS,
Abeona and Silverstein desire to amend the Agreement.

 

NOW,
THEREFORE, Abeona and Silverstein hereby agree to amend the Agreement as follows:

 

1.
The third sentence of the first paragraph of Section 4 of the Agreement is hereby amended to read in its entirety as follows:

 

“If
you remain continuously employed from the Effective Date through the date of a Change in Control (as defined below), notwithstanding
the terms of any equity incentive plan or award agreements, as applicable, all outstanding unvested stock options/stock appreciation
rights granted to your during your employment with the Company, including, without limitation, the Options, shall become fully
vested and exercisable immediately prior to the date of the Change in Control.”

 

2.
From and after the execution of this Amendment, all references in the Agreement to “this Agreement,” “hereof,”
“herein,” and similar words or phrases shall mean and refer to the Agreement as amended, including this Amendment.
This Amendment shall not be modified, supplemented, amended, or terminated in any manner whatsoever, except by a written instrument
signed by the party against which such modification, supplement, amendment, or termination is sought to be enforced.

 

3.
Except as expressly modified by this Amendment, all other terms and conditions of the Agreement shall remain in full force and
effect.

 

IN
WITNESS WHEREOF, Abeona and Silverstein have caused this Amendment to be executed by their respective duly authorized officers
as of the date first above written.

 

	/s/
    Christine Berni Silverstein	 	ABEONA
    THERAPEUTICS INC.
	Christine
    Berni Silverstein	 	By:	/s/
    Steven H. Rouhandeh
	 	 	Name: 	Steven
    H. Rouhandeh
	 	 	Title:	Executive
    ChairmanEXHIBIT 10.3

 

 

September
12, 2019

C/O
Edward Carr

 

Dear
Ed:

 

You
previously executed a letter offer of employment setting forth the terms of your employment as Chief Accounting Officer for Abeona
Therapeutics Inc. (the “Corporation”) dated as of October 17, 2018 (the “Offer”). We are hereby revising
the terms of your employment as follows:

 

		1.	The
                                         following section entitled “Severance” shall be added as the third section
                                         of the Offer:

 

“If
your employment is terminated by the Company other than for cause, in addition to any other amounts to which you may be entitled,
you will be entitled to a payment equal to the sum of fifty percent (50%) of your Base Salary plus fifty percent (50%) of your
target performance bonus.”

 

		2.	From
                                         and after the execution of this Amendment, all references in the Offer to “this
                                         offer,” “hereof,” “herein,” and similar words or phrases
                                         shall mean and refer to the Offer as amended, including this Amendment. This Amendment
                                         shall not be modified, supplemented, amended, or terminated in any manner whatsoever,
                                         except by a written instrument signed by the party against which such modification, supplement,
                                         amendment, or termination is sought to be enforced.

 

		3.	Except
                                         as expressly modified by this Amendment, all other terms and conditions of the Offer
                                         shall remain in full force and effect.

 

Please
acknowledge your acceptance of this offer by returning a signed copy of this letter.

 

	Very
    truly yours,	 	AGREED
    AND ACCEPTED:
	 	 	 
	/s/
    Kristina Maximenko	 	/s/
    Edward Carr
	VP,
    Human Resources	 	Edward
    Carr
	Abeona
    Therapeutics Inc.EXHIBIT 10.4

 

Certain
identified information has been excluded from this exhibit pursuant to Item 601(b)(10)(iv) of Regulation S-K because such information
both (i) is not material and (ii) would likely cause competitive harm if publicly disclosed. Excluded information is indicated
with brackets and asterisks.

 

FIRST
AMENDMENT TO LICENSE AGREEMENT

 

This
First Amendment to License Agreement (the “First Amendment”) is made as of November 4, 2019 (the “First
Amendment Effective Date”) by and between REGENXBIO Inc., a corporation organized under the laws of the State of Delaware,
with offices at 9600 Blackwell Road, Suite 210, Rockville, MD 20850 (“Licensor”), and Abeona Therapeutics Inc.,
a corporation organized under the laws of the State of Delaware, with offices at 1330 Avenue of the Americas, 33rd Floor, New
York, NY 10019 (“Licensee”). Licensor and Licensee are hereinafter referred to individually as a “Party”
and collectively as the “Parties.”

 

WHEREAS,
the Parties entered into that certain License Agreement dated November 4, 2018 (the “License Agreement”);

 

WHEREAS,
the Parties desire to amend certain provisions of the License Agreement relating to the timing of certain fees Licensee shall
pay Licensor under the License Agreement; and

 

WHEREAS,
pursuant to Section 10.9 of the License Agreement, the License Agreement may be amended, provided that such amendment is in
writing and signed by duly authorized representatives of both Parties.

 

NOW,
THEREFORE, in consideration of the promises and covenants contained in this First Amendment, and intending to be legally bound,
the Parties hereby agree as follows:

 

1. Section
3.1 of the License Agreement is hereby deleted in its entirety and replaced with the following:

 

“3.1
Initial Fee. In partial consideration of the rights and licenses granted to Licensee under this Agreement, Licensee shall
pay Licensor an initial fee of $21,000,000, which shall be payable as follows: (a) $10,000,000 within [****] after the Effective
Date; (b) $3,000,000 within twelve (12) months of the Effective Date; and (c) $8,000,000 no later than April 1, 2020, provided
that any unpaid portion of the initial fee (including (a), (b) and (c)) shall be immediately payable upon termination of this
Agreement or a Change of Control.”

 

2. This
First Amendment amends the terms of the License Agreement and is deemed incorporated into, and governed by all other terms of,
the License Agreement. To the extent that the License Agreement is explicitly amended by this First Amendment, the terms of this
First Amendment will control where the terms of the License Agreement are contrary to, or conflict with, the terms of this First
Amendment. All other terms and conditions of the License Agreement not explicitly amended by this First Amendment shall remain
in full force and effect. The License Agreement, shall, together with this First Amendment, be read and construed as a single
instrument.

 

3. Signatures
on this First Amendment may be communicated by facsimile or e-mail transmission and shall be binding upon the Parties upon receipt
by transmitting the same by facsimile or e-mail transmission, which signatures shall be deemed originals. If executed in counterparts,
this First Amendment shall be effective as if simultaneously executed.

 

[Remainder
of page intentionally left blank.]

 

    	 	 	 

    	 	 	 

    

 

IN
WITNESS WHEREOF, the Parties, intending to be legally bound, have caused this First Amendment to be executed by their duly
authorized representatives.

 

	REGENXBIO
    Inc.	 	Abeona
    Therapeutics Inc.
	 	 	 	 	 
	By:
    	/s/
    Kenneth T. Mills	 	By:
    	/s/
    Joao Siffert
	Name: 
    	Kenneth
    T. Mills	 	Name: 
    	Joao
    Siffert
	Title:
    	President
    and Chief Executive Officer	 	Title:
    	CEO
	Date:
    	November
    1, 2019	 	Date:
    	1-Nov-2019

 

    	 	2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}]]